Riperfusion therapy after stroke: success is higher when complement system is kept at bay

Reperfusion therapy, the gold standard for stroke treatment, helps restore blood flow after a stroke caused by a clot, preventing loss of brain tissue. However, only about 10% of stroke patients qualify, in part because of reperfusion therapy’s narrow treatment window. A recent Medical University of South Carolina study suggests that this therapy could be both safer and more effective for both motor and cognitive recovery if administered with a specialized compound that blocks the immune response. The team’s preclinical findings, reported in the Journal of Neuroscience, suggest that reducing the immune response in the brain could be a strategy for improving cognitive recovery. It could also extend the treatment window for therapy, allowing stroke specialists to help many more stroke patients. With reperfusion therapy the blood flow is restored, which is necessary to save the tissue, but there is an ongoing inflammatory response by the immune system that is not targeted by reperfusion. This could explain why, though mechanical reperfusion has a success rate of 90% in returning blood flow to the brain, only about 40% of treated patients recover enough motor and reasoning skills within three months to tend to their daily needs independently. Even those who do recover motor function can still struggle with cognitive challenges months later.

During a stroke, the oxygen and energy supply to the brain is cut off by a clot, causing brain tissue to become stressed and die rapidly. Just as it is with a cut to the knee, the immune system is activated to heal the wound, which includes clearing the dead tissue. A family of special immune proteins called complement proteins help to guide and promote this immune response in the damaged areas. In a 2018 article in Science Translational Medicine, the team showed that these complement proteins flagged both dead tissue and stressed brain cells for removal. The stressed brain cells were not yet dead, only damaged by lack of oxygen and energy. As the goal of stroke treatment is to save as much brain tissue as possible to lessen overall damage, this was a concerning result, as it meant salvageable tissue was being destroyed by the immune system. Therefore, the team developed a complement protein blocker, named B4Crry, which acts only at the site of stroke injury. This compound blinds the complement proteins to the signals of stressed brain cells, saving the stressed tissue and reducing overall brain damage in a preclinical stroke model. In the current study, they hypothesized that pairing reperfusion therapy and B4Crry would significantly improve stroke recovery beyond reperfusion therapy alone.

In particular, they hypothesized this combination treatment would improve cognitive recovery. As the team expected, reperfusion therapy alone did improve recovery of coordinated movements such as walking in a preclinical model of stroke. With the addition of B4Crry to treatment, coordinated movement improved even faster, with greater recovery seen as early as three days after the stroke. The improvements to learning and memory were even greater than those seen with motor functions. Reperfusion therapy alone was equal to no treatment at all for learning and memory recovery after stroke. However, when B4Crry was added to their treatments, mice had greatly improved cognitive recovery, making three times fewer errors on a learning and memory task. Scientists further probed into why the addition of B4Crry, and the subsequent reduction of the brain’s immune response, aided cognitive recovery so greatly. They found that after stroke, brain immune cells called microglia began eating the connections between stressed brain cells. Immune system complement proteins were marking these connections for destruction because they displayed the stressed cell signal. Without these connections, brain cells cannot communicate efficiently, and overall brain function decreases.

B4Crry concealed the cells’ stress signals from the complement proteins and thereby saved the connections between neurons. Preserving connectivity improved learning and memory brain function after stroke. A complement inhibitor such as B4Crry might also help stroke specialists overcome the biggest hurdle for reperfusion therapy: the short treatment window. The researchers showed that after clot removal adding B4Crry to reperfusion therapy reduced the potential for hemorrhage, or excessive bleeding, even with treatment given up to six hours after the stroke. These findings suggest that complement inhibition could not only make reperfusion therapy safer but extend its treatment window, making it available for many more stroke patients. The team at MUSC is also testing the potential for complement inhibitors in other brain injuries, such as traumatic brain injury. In preliminary tests they have shown that they can administer complement inhibitors as far as two months after a traumatic brain injury and see improvements in cognitive recovery. It means that months after an initial event, complement inhibitors could still be beneficial to cognitive recovery after brain injuries, including strokes.

  • Edited by Dr. Gianfrancesco Cormaci, PhD; specialist  in Clinical Biochemistry.

Scientific references

Alawieh AM et al. J Neurosci 2020 May 13; 40(20):4042.

Alawieh AM et al. Neurosurgery 2020 May 20:nyaa179. 

Anadani M et al. Stroke. 2019 Sep; 50(9):2448-2454.

0 0 vote
Article Rating
Informazioni su Dott. Gianfrancesco Cormaci 2445 Articoli
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry specialty in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Detentore di un brevetto sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of a patent concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica, salute e benessere sui siti web salutesicilia.com e medicomunicare.it
Subscribe
Notificami

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.

0 Commenti
Inline Feedbacks
View all comments